Signature for Precise Chemosensitivity Prediction in PDAC

Ruijin Hospital365 enrolled

Overview

Pancreatic ductal adenocarcinoma (PDAC) is largely heterogeneous. We sought to develop and validate a signature to precisely predict chemotherapy sensitivity in PDAC. Genetic events of the four most commonly mutated genes in PDAC and expressions of 12 PI3K/AKT/mTOR pathway markers were examined in consecutive patients with PDAC. A 9-feature signature for prediction of chemotherapy benefits was constructed using the LASSO Cox regression model, and validated in two independent cohorts.

Study Type

OBSERVATIONAL

Enrollment

365

Conditions

Pancreatic Cancer

Interventions

ChemotherapyDRUG

All adjuvant chemotherapy for nonmetastatic PDAC was gemcitabine-based (Cycle \>= 1).

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ECOG performance status score of 0-1 before resection * complete clinicopathologic and follow-up data * availability of formalin-fixed paraffin-embedded (FFPE) specimens of resected primary tumor and hematoxylin and eosin slides with invasive tumor components Exclusion Criteria: * any previous history of cancer * any anticancer therapy prior to resection or adjuvant radiotherapy * metastatic cases * major postsurgical complications with Clavien-Dindo Grade ≥2

Locations (1)

Ruijin Hospital

Shanghai, China

Outcomes

Primary Outcomes

Overall survival

Time between resection and death of any cause

Time frame: 3-year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.